Investigation of plasma metabolomics and neurotransmitter dysfunction in the process of Alzheimer's disease rat induced by amyloid beta 25-35

被引:5
|
作者
Wei, Mengying [1 ,2 ]
Liu, Yuanyuan [1 ]
Pi, Zifeng [2 ]
Yue, Kexin [1 ]
Li, Shizhe [3 ]
Hu, Mingxin [1 ]
Liu, Zhiqiang [2 ]
Song, Fengrui [2 ]
Liu, Zhongying [1 ]
机构
[1] Jilin Univ, Sch Pharmaceut Sci, 1266 Fujin Rd, Changchun 130021, Jilin, Peoples R China
[2] Chinese Acad Sci, Changchun Inst Appl Chem, Natl Ctr Mass Spectrometry Changchun, Jilin Prov Key Lab Chinese Med Chem & Mass Spectr, Changchun 130022, Jilin, Peoples R China
[3] Guangdong Univ Technol, Inst Biomed & Pharmaceut Sci, Guangzhou 510006, Guangdong, Peoples R China
基金
中国国家自然科学基金;
关键词
ARACHIDONIC-ACID; NITRIC-OXIDE; FATTY-ACIDS; DEMENTIA; SYSTEMS; CHOLESTEROL; NEUROINFLAMMATION; HOMOCYSTEINE; INFLAMMATION; HIPPOCAMPUS;
D O I
10.1039/c9ra00302a
中图分类号
O6 [化学];
学科分类号
0703 ;
摘要
Alzheimer's disease (AD) has become one of the major diseases endangering the health of the elderly. Clarifying the features of each AD animal model is valuable for understanding the onset and progression of diseases and developing potential treatments in the pharmaceutical industry. In this study, we aimed to clarify plasma metabolomics and neurotransmitter dysfunction in the process of AD model rat induced by amyloid beta 25-35 (A beta 25-35). Firstly, Morris Water Maze (MWM) test was used to investigate cognitive impairment in AD rat after 2, 4 and 8 weeks of modelling. Based on this, the effects on levels of AD-related enzymes and eight neurotransmitters were analyzed. And plasma metabolomics analysis based on ultra high-performance liquid chromatography coupled with quadrupole time-of-flight mass spectrometry (UHPLC-Q-TOF-MS) was used to research the metabolic disturbances in the process of AD rat. The results shown the injury on the spatial learning ability of AD rats was gradually aggravated within 4 weeks, reached the maximum at 4 weeks and then was stable until 8 weeks. During 8 weeks of modeling, the levels of enzymes including beta-secretase, gamma-secretase, glycogen synthase kinase-3 beta (GSK-3 beta), acetyl cholinesterase (AchE) and nitric oxide synthase (NOS) were significant increased in the plasma of AD rats. The neurotransmitter dysfunction was mainly involved in gamma-aminobutyric acid (GABA), acetyl choline (Ach), glutamic acid (Glu), 5-hydroxytryptamine (5-HT), dopamine (DA) and norepinephrine (NE). 17 endogenous metabolites correlated with AD were successfully detected in the metabolomics analysis. These metabolites were mainly involved in fatty acids, sphingolipids, and sterols metabolisms, vitamin metabolism, and amino acid metabolism. These metabolites might be the potential biomarkers that correctly mark different stages of AD. The study on peripheral plasma indices reflecting the process of AD laid the foundation for understand the pathophysiology of AD and find an effective and radical cure. And the rules of endogenous metabolic disorder in AD rats also have a certain guiding significance for the future study of food-drug interactions at different stages of AD.
引用
收藏
页码:18308 / 18319
页数:12
相关论文
共 50 条
  • [1] Investigation of plasma metabolomics and neurotransmitter dysfunction in the process of Alzheimer's disease rat induced by amyloid beta 25-35 (vol 9, pg 18308, 2019)
    Wei, Mengying
    Liu, Yuanyuan
    Pi, Zifeng
    Yue, Kexin
    Li, Shizhe
    Hu, Mingxin
    Liu, Zhiqiang
    Song, Fengrui
    Liu, Zhongying
    RSC ADVANCES, 2021, 11 (13) : 7416 - 7416
  • [2] Varenicline Ameliorates Learning and Memory Deficits in Amyloid beta(25-35) Rat Model of Alzheimer's Disease
    Baluchnejadmojarad, Tourandokht
    Roghani, Mehrdad
    Karimi, Narges
    Kamran, Mitra
    BASIC AND CLINICAL NEUROSCIENCE, 2011, 3 (01) : 48 - 57
  • [3] NOOTROPIC ACTIVITY OF ISORHAMNETIN IN AMYLOID BETA 25-35 INDUCED COGNITIVE DYSFUNCTION AND ITS RELATED mRNA EXPRESSIONS IN ALZHEIMER'S DISEASE
    Asha, Deivasigamani
    Sumathi, Thangarajan
    INTERNATIONAL JOURNAL OF PHARMACEUTICAL SCIENCES AND RESEARCH, 2016, 7 (08): : 3233 - 3242
  • [4] Gene Expression Profile of Hippocampus in Aβ (25-35) Induced Alzheimer's Disease Model Rat
    Huang, F. J.
    Tian, X. X.
    Li, W. P.
    Li, Y. H.
    Shen, J. G.
    Wu, Z. Z.
    JOURNAL OF THE AMERICAN GERIATRICS SOCIETY, 2016, 64 : S341 - S341
  • [5] β-amyloid peptide (25-35) as a tool for in vivo modelling Alzheimer's disease in rats
    Stepanichev, MY
    Onufriev, MV
    Moiseeva, YV
    Lazareva, NA
    Alessenko, AV
    Victorov, IV
    Gulyaeva, NV
    JOURNAL OF NEUROCHEMISTRY, 2001, 77 : 19 - 19
  • [6] Memory and Brain Neurotransmitter Restoring Potential of Hydroalcoholic Extract of Ipomoea aquatica Forsk on Amyloid Beta Aβ (25-35) Induced Cognitive Deficits in Alzheimer's Mice
    Sivaraman, D.
    Panneerselvam, P.
    Muralidharan, P.
    INTERNATIONAL JOURNAL OF PHARMACOLOGY, 2016, 12 (02) : 52 - 65
  • [7] Role of amyloid beta (25-35) neurotoxicity in the ferroptosis and necroptosis as modalities of regulated cell death in Alzheimer's disease
    Naderi, Soudabeh
    Khodagholi, Fariba
    Pourbadie, Hamid Gholami
    Naderi, Nima
    Rafiei, Shahrbanoo
    Janahmadi, Mahyar
    Sayehmiri, Fatemeh
    Motamedi, Fereshteh
    NEUROTOXICOLOGY, 2023, 94 : 71 - 86
  • [8] Alzheimer's disease amyloid beta peptide 25-35 inhibits lipid peroxidation as a result of its membrane interactions
    Waiter, MF
    Mason, PE
    Mason, RP
    BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS, 1997, 233 (03) : 760 - 764
  • [9] The behavior and neurotransmitter contents in brain structures of rats with Alzheimer's disease modeled by administration of Aβ25-35
    Litvinova, S. A.
    Klodt, P. M.
    Kudrin, V. S.
    Narkevich, V. B.
    Voronina, T. A.
    NEUROCHEMICAL JOURNAL, 2015, 9 (01) : 39 - 46
  • [10] β-amyloid fragment 25-35 selectively damages platelets from patients with Alzheimer's disease
    Casoli, T
    Di Stefano, G
    Delfino, A
    Solazzi, M
    Fattoretti, P
    Bertoni-Freddari, C
    Guidi, M
    Scarpino, O
    Giunta, S
    Galeazzi, L
    ALZHEIMER'S DISEASE: VASCULAR ETIOLOGY AND PATHOLOGY, 2002, 977 : 296 - 302